Abstract 1728P
Background
The prevalence of oncology survivors is increasing exponentially. More than half of them experience difficulty in returning to their pre-disease socio-familial role. Comprehensive Oncology Units are infrequent in our environment. In our center we have implemented this novel Unit in order to improve the quality of life of our cancer survivors during follow-up.
Methods
Prospective quasi-experimental study. From March 2022 to March 2023. A total of 232 patients were included in the Comprehensive Oncology Unit of the Juan Ramón Jiménez Hospital in Huelva. The aim of our study is to describe the psychosocial, nutritional and physical needs of cancer survivors during follow-up and the impact of the intervention on their quality of life.
Results
The median age of the patients was 53 years (33 - 78). Ninety-six percent were women. Ninety percent had been diagnosed with breast cancer, followed by 6 % CRC, 2 % other digestive tumors and 2 % gynecological tumors. 67.1% required assessment for nutrition, 62.9% for rehabilitation, 59.28% for psycho-oncology and 4.8% for social intervention. Of the patients who were evaluated by psycho-oncology, 50% improved their fear of recurrence with only 3 sessions. Regarding nutrition assessment, the median BMI in the population with BMI > 25kg/m2 was 30.7 Kg/m2 at baseline and 29.71 Kg/m2 (22.7 - 40) 6 months after nutrition intervention (p<0.001).
Conclusions
The results of our study reveal that there is a high demand of needs to be covered in cancer survivors beyond the purely clinical aspects that impact on their quality of life. Implementing a Comprehensive Oncology Unit could help to detect these needs and improve their healthy lifestyle habits as well as improve their quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Comprehensive Oncology Unit.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23